

MitoXpress™ –Xtra assay: End user publications

MitoXpress probes are making an impact in the drug safety community. For example, Pfizer Drug Safety Research and Development (DSRD) group, san Diego, CA, has validated MitoXpress as an early high throughput screen of NCE's for mitochondrial toxicity. This Pfizer validation has been reported in a number of publications, detailed below.

Isolated mitochondrial and cell-based studies (Pfizer publications)

- Will, Y., et al., Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. *Nature Protocols*, 2007. 1(6): p. 2563-2572.
- Dykens, J., et al., Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. *Expert Rev Mol Diagn.* 2007 Mar;7(2):161-75
- Hynes, J., et al., Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. *Toxicological Sciences*, 2006. 92(1): p. 186-200.

General principles of optical oxygen sensing and respirometry (Luxcel publications)

- Papkovsky D.P., *Methods Enzymol.*, 2004, V. 381, p. 715-735.
- Papkovsky D.P. et al., *Expert Opin. Drug Metab. Toxicol*, 2006, v. 2 (2), p. 313-323